MTOR and cancer: Importantly, the paradoxical effect of mTOR inhibitors on immunity has also been observed in cancer patients where the rapamycin analog everolimus simultaneously promoted high expansion of regulatory CD4+ T cells and activated tumor-specific Th1 immunity [8].